Introducing EpiCube: Powerful Epidemiology Data Analysis with Power BI visualization

EpiCube is not just another epidemiology database.

With extensive datasets and Power BI-driven, dynamic reports, it transforms traditional data analysis into a visually immersive journey. Unlike sifting through Excel files or databases, EpiCube provides a more engaging and intuitive way to explore epidemiology data, supporting your forecasting.

We have designed EpiCube to enable effortless filtering of data by specific diseases, providing both macro and micro-level analyses. Its user-friendly interface allows you to visually explore disease-specific details, such as incidence rates, biomarkers, and gender splits, making analysis quicker and less error-prone compared to traditional methods.

EpiCube Coverage

In terms of coverage for oncology forecasting, EpiCube stands out, offering unrivalled analytical capabilities.

Explore and analyse your data, filtering by various criteria. The granular detail goes beyond incidence and prevalence rates to include factors like country, gender splits, age groups, and severity categories, facilitating a detailed exploration of the dataset.

EpiCube for Market Research

EpiCube is a valuable tool for both secondary and primary market research.

Secondary Research

Primary Research

EpiCube’s flexibility allows the extraction of data into Excel or CSV files while maintaining the efficiency and clarity of Power BI reports. In-built AI helps you to explore data deviations, for error-free analysis.

Created by the experts at J+D with pharmaceutical forecasting structures in mind, easily align your EpiCube data with your forecast with complete transparency, providing confidence in both the inputs and outputs of your forecast.

Speak with an expert

more insights

Our Pharmaceutical Forecasting Predictions for 2024

As the pharmaceutical industry contends with growing financial pressures, we examine its strategic outlook for 2024. How does the sector intend to align with projected commercial objectives while continuing to meet patient needs and what are the implications for forecasting teams?

Read more >